Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov 22:4:146.
doi: 10.3389/fphar.2013.00146.

Mechanisms of antidepressant resistance

Wissam El-Hage  1 , Samuel Leman, Vincent Camus, Catherine Belzung
Affiliations
Review

Mechanisms of antidepressant resistance

Wissam El-Hage et al. Front Pharmacol. .

Abstract

Depression is one of the most frequent and severe mental disorder. Since the discovery of antidepressant (AD) properties of the imipramine and then after of other tricyclic compounds, several classes of psychotropic drugs have shown be effective in treating major depressive disorder (MDD). However, there is a wide range of variability in response to ADs that might lead to non response or partial response or in increased rate of relapse or recurrence. The mechanisms of response to AD therapy are poorly understood, and few biomarkers are available than can predict response to pharmacotherapy. Here, we will first review markers that can be used to predict response to pharmacotherapy, such as markers of drug metabolism or blood-brain barrier (BBB) function, the activity of specific brain areas or neurotransmitter systems, hormonal dysregulations or plasticity, and related molecular targets. We will describe both clinical and preclinical studies and describe factors that might affect the expression of these markers, including environmental or genetic factors and comorbidities. This information will permit us to suggest practical recommendations and innovative treatment strategies to improve therapeutic outcomes.

Keywords: antidepressants; major depression; monoamine; resistance; treatment-resistant depression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms (in blue) associated with antidepressant therapy resistance and recommendations for clinical practice (in green).
See this image and copyright information in PMC

References

    1. Adachi M., Barrot M., Autry A. E., Theobald D., Monteggia L. M. (2008). Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol. Psychiatry 63, 642–649 10.1016/j.biopsych.2007.09.019 - DOI - PMC - PubMed
    1. Agid O., Lerer B. (2003). Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int. J. Neuropsychopharmacol. 6, 41–49 10.1017/S146114570200322X - DOI - PubMed
    1. Airan R. D., Meltzer L. A., Roy M., Gong Y., Chen H., Deisseroth K. (2007). High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 317, 819–823 10.1126/science.1144400 - DOI - PubMed
    1. Akerblad A. C., Bengtsson F., von Knorring L., Ekselius L. (2006). Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int. Clin. Psychopharmacol. 21, 117–124 10.1097/01.yic.0000199452.16682.b8 - DOI - PubMed
    1. Alexander B., Warner-Schmidt J., Eriksson T., Tamminga C., Arango-Lievano M., Ghose S., et al. (2010). Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Science Transl. Med. 2, 54ra76 10.1126/scitranslmed.3001079 - DOI - PMC - PubMed